This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Receptor modulators edit
Monoamine receptor modulators edit
- Brilaroxazine (RP5063; oxaripiprazole) – atypical antipsychotic (D2/3/4 and 5-HT1A partial agonist and 5-HT2A/2B/7 antagonist)[1]
- FKF-02SC (TGOF-02N) – atypical antipsychotic (D2 and 5-HT2A receptor antagonist, other actions)[2]
- Masupirdine (SUVN-502) – 5-HT6 receptor antagonist[3]
- N-methyl amisulpride (LB-102) – D2,3, 5-HT7, receptor antagonists (methylated version of amisulpride)[4]
- Ralmitaront (RG-7906, RO-6889450) – TAAR1 agonist[5]
- Ulotaront (SEP-856, SEP-363856) – 5-HT1A receptor and TAAR1 agonist[6]
- Usmarapride (SUVN-D4010) – 5-HT4 receptor partial agonist[7]
Glutamate receptor modulators edit
- Pomaglumetad methionil (DB-103, LY-2140023, LY-2812223) – mGluR2 and mGluR3 agonist[8]
Acetylcholine receptor modulators edit
- Emraclidine (CVL-231) – M4 muscarinic acetylcholine receptor positive allosteric modulator.[9]
- KarXT (xanomeline/trospium) – combined M1 and M4 muscarinic acetylcholine receptor agonist and peripherally-selective muscarinic acetylcholine receptor antagonist.[10]
- ML-007 – M1 and M4 muscarinic acetylcholine receptor agonist.[11]
- NBI-1117568 (HTL 0016878) – M4 muscarinic acetylcholine receptor agonist.[12]
Cannabinoid receptor modulators edit
- Cannabidiol (CBD; GW-42003, GWP-42003, GWP-42003-P, ECP-012A; Arvisol, Epidiolex) – cannabinoid receptor modulator, antioxidant, other actions[13][14]
Other/mixed receptor modulators edit
- CVN766 – Orexin receptor type 1 antagonist[15]
- Deudextromethorphan (d-DM; AVP-786, CTP-786) – σ1 receptor agonist, serotonin–norepinephrine reuptake inhibitor, uncompetitive NMDA receptor antagonist, muscarinic acetylcholine receptor agonist, other actions[16][17]
- Roluperidone (CYR-101, MIN-101, MT-210) – 5-HT2A and σ2 receptor antagonist[18]
- TAK-041 (NBI 1065846) – GPR139 receptor agonist[19]
Enzyme inhibitors edit
- Luvadaxistat (NBI 1065844, TAK-831) – D-amino acid oxidase inhibitor.[20]
- MK-8189 – phosphodiesterase 10A inhibitor.[21]
- Osoresnontrine (BI-409306, SUB-166499) – phosphodiesterase 9A inhibitor[22]
- Sodium benzoate (SND-11, SND-12, SND-13, SND-14; Clozaben, NaBen) – D-amino acid oxidase inhibitor[23]
Ion channel modulators edit
Others edit
See also edit
References edit
- ^ "Brilaroxazine - Reviva Biopharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "FKF 02SC - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Masupirdine - Suven Life Sciences - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "N-methyl amisulpride - LB pharmaceuticals - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-21.
- ^ "Ralmitaront - AdisInsight". adisinsight.springer.com. Springer. Retrieved 10 July 2021.
- ^ "SEP 363856 - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "SUVN D4010 - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Pomaglumetad methionil - Denovo Biopharma/Eli Lilly and Company - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Emraclidine - Cerevel Therapeutics - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-15.
- ^ "APN 1125 - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "ML 007 - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-15.
- ^ "HTL 0016878 - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-21.
- ^ "Cannabidiol - GW Pharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Cannabidiol - Echo Pharmaceuticals - AdisInsight". adisinsight.springer.com. Retrieved 14 February 2020.
- ^ "CVN 766 - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-19.
- ^ "Deudextromethorphan - Avanir Pharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ Nguyen, Linda; Thomas, Kelan L.; Lucke-Wold, Brandon P.; Cavendish, John Z.; Crowe, Molly S.; Matsumoto, Rae R. (March 2016). "Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders". Pharmacology & Therapeutics. 159: 1–22. doi:10.1016/j.pharmthera.2016.01.016. ISSN 1879-016X. PMID 26826604.
- ^ "Roluperidone - Minerva Neurosciences - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "TAK 041 - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-21.
- ^ "Luvadaxistat - Takeda - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-21.
- ^ "MK 8189 - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-21.
- ^ "BI 409306 - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Sodium benzoate - SyneuRx - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Evenamide - Newron Pharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "TS 134 - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ Vijeepallam, K.; Pandy, V.; Kunasegaran, T.; Murugan, D. D.; Naidu, M. (2016). "Mitragyna speciosa Leaf Extract Exhibits Antipsychotic-Like Effect with the Potential to Alleviate Positive and Negative Symptoms of Psychosis in Mice". Frontiers in Pharmacology. 7: 464. doi:10.3389/fphar.2016.00464. PMC 5138496. PMID 27999544.
- ^ Johnson, L. E.; Balyan, L.; Magdalany, A.; Saeed, F.; Salinas, R.; Wallace, S.; Veltri, C. A.; Swogger, M. T.; Walsh, Z.; Grundmann, O. (2020). "The Potential for Kratom as an Antidepressant and Antipsychotic". The Yale Journal of Biology and Medicine. 93 (2): 283–289. PMC 7309668. PMID 32607089.